Chemomab Therapeutics (CMMB) Competitors $1.38 -0.04 (-2.82%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CMMB vs. STTK, AVTE, RPHM, ZIVO, IMRX, MURA, GMTX, KRON, BRNS, and DTILShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Shattuck Labs (STTK), Aerovate Therapeutics (AVTE), Reneo Pharmaceuticals (RPHM), ZIVO Bioscience (ZIVO), Immuneering (IMRX), Mural Oncology (MURA), Gemini Therapeutics (GMTX), Kronos Bio (KRON), Barinthus Biotherapeutics (BRNS), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Shattuck Labs Aerovate Therapeutics Reneo Pharmaceuticals ZIVO Bioscience Immuneering Mural Oncology Gemini Therapeutics Kronos Bio Barinthus Biotherapeutics Precision BioSciences Chemomab Therapeutics (NASDAQ:CMMB) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Do analysts rate CMMB or STTK? Chemomab Therapeutics presently has a consensus price target of $5.67, indicating a potential upside of 310.63%. Shattuck Labs has a consensus price target of $8.67, indicating a potential upside of 593.33%. Given Shattuck Labs' higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Shattuck Labs 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.40 Does the MarketBeat Community prefer CMMB or STTK? Shattuck Labs received 20 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 74.00% of users gave Shattuck Labs an outperform vote while only 62.96% of users gave Chemomab Therapeutics an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1762.96% Underperform Votes1037.04% Shattuck LabsOutperform Votes3774.00% Underperform Votes1326.00% Is CMMB or STTK more profitable? Chemomab Therapeutics has a net margin of 0.00% compared to Shattuck Labs' net margin of -2,067.99%. Shattuck Labs' return on equity of -68.65% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -102.80% -76.79% Shattuck Labs -2,067.99%-68.65%-60.38% Does the media favor CMMB or STTK? In the previous week, Shattuck Labs had 4 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 5 mentions for Shattuck Labs and 1 mentions for Chemomab Therapeutics. Shattuck Labs' average media sentiment score of 0.21 beat Chemomab Therapeutics' score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, CMMB or STTK? Chemomab Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Which has preferable earnings and valuation, CMMB or STTK? Chemomab Therapeutics has higher earnings, but lower revenue than Shattuck Labs. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$1.14-1.21Shattuck Labs$1.66M35.94-$87.30M-$1.85-0.68 Do insiders and institutionals hold more shares of CMMB or STTK? 46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryShattuck Labs beats Chemomab Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.82M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E Ratio-1.219.36112.5515.07Price / SalesN/A386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book0.905.324.645.01Net Income-$24.22M$153.56M$119.13M$225.46M7 Day Performance-4.17%0.12%0.78%0.37%1 Month Performance-8.61%15.23%5.65%3.57%1 Year Performance81.67%41.16%36.90%29.42% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics2.5672 of 5 stars$1.38-2.8%$5.67+310.6%+89.0%$19.82MN/A-1.2120Gap DownSTTKShattuck Labs3.5867 of 5 stars$1.31+2.3%$8.67+561.6%-22.4%$62.29M$4.12M-0.71100Gap DownHigh Trading VolumeAVTEAerovate Therapeutics1.5464 of 5 stars$2.12+1.0%$2.25+6.1%-73.8%$61.10MN/A-0.6851News CoverageRPHMReneo Pharmaceuticals2.3163 of 5 stars$1.82+5.2%$11.01+505.1%-76.8%$60.84MN/A-0.8430Gap DownZIVOZIVO BioscienceN/A$18.05-9.8%N/A+712.5%$59.91M$15,850.00-3.4310Positive NewsIMRXImmuneering3.7702 of 5 stars$2.01-6.5%$12.60+526.9%-71.1%$59.60M$320,000.00-1.0560Short Interest ↓News CoveragePositive NewsMURAMural Oncology3.7954 of 5 stars$3.51+0.6%$16.00+355.8%N/A$59.40MN/A-0.34119GMTXGemini TherapeuticsN/A$46.01+0.0%N/A+2.9%$58.49MN/A-46.0130High Trading VolumeKRONKronos Bio3.5633 of 5 stars$0.97+2.1%$4.13+325.3%+17.4%$58.48M$6.29M-0.56100Short Interest ↓News CoverageBRNSBarinthus Biotherapeutics3.48 of 5 stars$1.49+4.2%$5.83+291.5%N/A$58.16M$800,000.00-0.90107Short Interest ↓News CoverageDTILPrecision BioSciences4.0207 of 5 stars$8.37-1.3%$39.50+371.9%-24.6%$57.97M$87.64M40.26200Upcoming Earnings Related Companies and Tools Related Companies STTK Competitors AVTE Competitors RPHM Competitors ZIVO Competitors IMRX Competitors MURA Competitors GMTX Competitors KRON Competitors BRNS Competitors DTIL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMMB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
